Monoclonal Antibodies

A new study found that several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the Omicron variant now sweeping across the United States. Read More

Five monoclonal antibody “cocktails,” including one developed at Vanderbilt University Medical Center (VUMC), are protective in animal studies against several variant strains of COVID-19, according to a report this week in the journal Nature. Read More

Vanderbilt Vaccine Center researchers have isolated monoclonal antibodies against hantaviruses, an emerging source of human disease with pandemic potential. Read More

The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development. Read More

A monoclonal antibody “cocktail” developed at Vanderbilt University Medical Center to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus, according to a report published today in the journal Nature Medicine.... Read More

Evotec, a drug company headquartered in Hamburg, Germany, has begun a phase 1 clinical trial of a monoclonal antibody against the chikungunya virus that was identified at Vanderbilt University Medical Center. Read More

The isolation of human monoclonal antibodies against dangerous viruses including EEEV, Hendra and Nipah could offer new ways to treat and prevent these infections. Read More

James Crowe Jr., MD, a physician-scientist at Vanderbilt University Medical Center who has pioneered development of human monoclonal antibodies as potential treatments for viral diseases, has won a 2020 “Golden Goose” Award. Read More

Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19. Read More

Researchers at Vanderbilt University Medical Center, Purdue University and the University of Wisconsin-Madison have isolated human monoclonal antibodies that potentially can prevent a rare but devastating polio-like illness in children linked to a respiratory viral infection. Read More

After evaluating the ability of more than 1,500 monoclonal antibodies to bind and neutralize the COVID-19 virus, SARS-CoV-2, in the laboratory, AstraZeneca signed an exclusive license to six candidate antibodies in Vanderbilt’s portfolio. Read More

Vanderbilt Vaccine Center team isolates monoclonal antibodies against the mosquito-borne Ross River virus, which causes rash, fever and debilitating muscle and joint pain lasting three to six months. Read More

Monoclonal antibodies against Marburg virus — a more lethal cousin of the RNA virus that causes COVID-19 — may aid in the development of antibody "cocktails" to counter viral infection. Read More

Targeting the protein that mosquito-borne viruses use to enter cells could be a strategy for preventing infection by multiple emerging viruses. Read More

Few people die from rabid animal bites in the United States thanks to the near-universal availability of human rabies immune globulin and rabies vaccine, which are given as separate shots as soon as possible after exposure to the rabies virus. Read More

Newly discovered features in an RSV protein may be useful for rational structure-based vaccine design. Read More

Vanderbilt investigators have discovered a novel non-genetic cause of resistance to the targeted anti-cancer therapy cetuximab. Their findings, reported this week in Nature Medicine, suggest a strategy for overcoming this resistance. Read More

Scott Smith, M.D., Ph.D., assistant professor of Medicine, has received a 2017 research award from the Stanley Cohen Innovation Fund to test a new therapeutic strategy for peanut allergies. Smith's research could fundamentally change allergy treatment. Read More

Researchers at Vanderbilt University Medical Center (VUMC) have taken another step toward developing a vaccine against respiratory syncytial virus (RSV), the major cause of life-threatening pneumonia in infants worldwide. Read More

To prepare for the potential of a smallpox return, Vanderbilt researchers are isolating and studying naturally occurring antibodies from the blood of previously infected or immunized people. Read More